StockNews.AISignal intelligence
ACADIA Pharmaceuticals Inc. · NASDAQ · Healthcare
Browse public ACAD signals with their source context and measured market impact. Open any signal for its permanent analysis page.
ACADIA shares rise after the CHMP recommends EU marketing authorization for DAYBU trofinetide, buoyed by positive LAVENDER Phase 3 results. With the stock trading around $26.57 and approaching $28 resistance, momentum looks strong but overbought, while a death cross warns of longer-term caution.
View signal analysisACAD's Phase 3 trial for carbetocin failed primary efficacy endpoint. CEO assures long-term growth despite recent trial results. Company expects significant sales growth and multiple new study starts by 2026. ACAD stock dropped 11.02% premarket following trial results. Competitor Soleno Therapeutics faces scrutiny for its PWS treatment.
View signal analysisACAD's experimental therapy failed to achieve goals in late-stage study. This setback may impact investor confidence in ACAD's pipeline.
View signal analysisACAD secured a favorable court ruling for NUPLAZID's patent protection. The ruling extends protection against generics until 2038. ACAD shares rose by 26.5% following the announcement. Analysts raised price targets for ACADIA after the ruling. Needham and HC Wainwright maintain 'Buy' ratings on ACAD.
View signal analysis